Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics (CORT)
:CORT
CORT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.84 - $75.00
Previous CloseN/A
Volume78.39K
Average Volume (3M)1.16M
Market Cap
$6.19B
Enterprise Value$4.89B
Total Cash (Recent Filing)$127.67M
Total Debt (Recent Filing)$6.94M
Price to Earnings (P/E)47.6
Beta1.29
Next Earnings
Apr 30, 2025EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.23
Shares Outstanding105,503,430
10 Day Avg. Volume1,056,305
30 Day Avg. Volume1,158,264
Financial Highlights & Ratios
PEG Ratio1.48
Price to Book (P/B)N/A
Price to Sales (P/S)9.17
Price to Cash Flow (P/CF)26.10
P/FCF Ratio26.10
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.36
Enterprise Value/Ebitda35.55
Forecast
1Y Price Target
$109.50Price Target Upside86.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Corcept Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Growth OutlookThe company's FY2025 revenue guidance of $900-950M is higher than the prior estimate and the consensus, showing expectations of continuous growth.
Market PotentialRelacorilant is not restricted to a single genetic sub-group of patients like Elahere, potentially allowing broader applicability.
Regulatory ProgressThe FDA has accepted the NDA submission for relacorilant in Cushing's for filing, moving it one step closer to approval.
Bears Say
Operational ChallengesThe demand for Korlym exceeded the processing capacity of the company's pharmacy vendor during 4Q24, which could result in lower revenue for 1Q25 relative to the rest of 2025.
Revenue MissThe company reported total revenues of approximately $181.9M for the quarter, compared to the consensus estimate of $198.7M, and a net profit of $0.26 per diluted share, compared to the consensus estimated net profit of $0.43 per share.
---
Ownership Overview
15.17% Insiders
17.70% Mutual Funds
16.74% Other Institutional Investors
26.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CORT FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest stock price was $20.84 and its highest was $75.00 in the past 12 months.
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is $6.19B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s upcoming earnings report date is Apr 30, 2025 which is in 36 days.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Feb 26, 2025. The company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.426 by -$0.166.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 0.15.
How many shares outstanding does Corcept Therapeutics have?
Corcept Therapeutics has 105,503,430 shares outstanding.
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of $0.26 in its last earnings report, missing expectations of $0.426. Following the earnings report the stock price went down -5.555%.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Currently, no hedge funds are holding shares in CORT
---
Corcept Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$109.50 (86.67% Upside)
$109.50 (86.67% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 22.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $226.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.01%
12-Months-Change
Fundamentals
Return on Equity
23.55%
Trailing 12-Months
Asset Growth
35.24%
Trailing 12-Months
Company Description
Corcept Therapeutics
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
---
CORT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Corcept Therapeutics demonstrated strong financial performance with significant revenue and net income growth. The company made substantial progress in drug development, notably with relacorilant for hypercortisolism and potential cancer treatments. However, they faced operational challenges affecting revenue and a legal setback with Teva. Despite these issues, the overall outlook remains positive due to strategic advancements and strong financials.Read More>---
CORT Stock 12 Month Forecast
Average Price Target
$109.50
▲(86.67% Upside)
Technical Analysis
Amgen
―
Neurocrine
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
SAGE Therapeutics
―
Best Analysts Covering CORT
1 Year
1 Year Success Rate
13/14 ratings generated profit
1 Year Average Return
+60.32%
reiterated a buy rating 26 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +60.32% per trade.
---